Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14239233 | 0.92 | TERT (0.49) | TERTMEN1KMT2APTPRCPTPN13 | |
| SCHEMBL12110536 | 0.88 | TERT (0.50) | TERTMEN1KMT2APTPRCPTPN13 | |
| SCHEMBL14239610 | 0.85 | TERT (0.52) | TERTMEN1KMT2APTPRCPTPN13 | |
| SCHEMBL14240029 | 0.83 | TERT (0.50) | TERTMEN1KMT2APTPRCPTPN13 | |
| SCHEMBL14240483 | 0.78 | TERT (0.56) | TERTMEN1KMT2APTPRCPTPN13 | |
| SCHEMBL14151673 | 0.78 | TERT (0.52) | TERTMEN1KMT2APTPRCPTPN13 | |
| SCHEMBL14240478 | 0.77 | TERT (0.53) | TERTMEN1KMT2APTPRCPTPN13 | |
| SCHEMBL14239232 | 0.77 | TERT (0.53) | TERTMEN1KMT2APTPRCPTPN13 | |
| SCHEMBL14240031 | 0.76 | PTPRC (0.58) | TERTMEN1KMT2APTPRCPTPN13 | |
| SCHEMBL13343847 | 0.75 | ALDH1A1 (0.48) | TERTMEN1KMT2APTPRCPTPN13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316234-A1 | ANTHRAQUINONE -BASED COMPOUND, THE SYNTHESIS PROCESSES AND THE APPLICATION THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316234-A1 | ANTHRAQUINONE -BASED COMPOUND, THE SYNTHESIS PROCESSES AND THE APPLICATION THEREOF | AAAS, QPCT, NQO2 | TERT 2376/4885MEN1 2110/4885KMT2A 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.